RECK, a novel matrix metalloproteinase regulator

Histology and Histopathology

Volumn 23, Issue 8, 2008, Pages 1003-1010

  Meng, N ^a   Li, Y ^a   Zhang, H ^b   Sun, X F ^c  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF SKÖVDE   (Sweden)

^c LINKÖPING UNIVERSITY   (Sweden)

Author keywords

MMPs; RECK; TIMPs

Indexed keywords

MATRIX METALLOPROTEINASE; MEMBRANE PROTEIN; RECK PROTEIN, HUMAN; TISSUE INHIBITOR OF METALLOPROTEINASE;

CELL CULTURE; CELL TRANSFORMATION; CHEMISTRY; DOWN REGULATION; DRUG ANTAGONISM; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION; HUMAN; METABOLISM; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PHYSIOLOGY; REVIEW; VASCULARIZATION;

CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; DOWN-REGULATION; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MATRIX METALLOPROTEINASES; MEMBRANE GLYCOPROTEINS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 46249116531     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. Bode W. and Maskos K. (2001). Structural studies on MMPs and TIMPs. Methods Mol. Biol. 151, 45-77.
2. Chadjichristos C., Ghayor C., Herrouin J.F., Ala-Kokko L., Suske G., Pujol J.P. and Galera P. (2002). Down-regulation of human type II collagen gene expression by transforming growth factor-beta 1 (TGF-beta 1) in articular chondrocytes involves SP3/SP1 ratio. J. Biol. Chem. 277, 43903-43917.
3. Chang H.C., Liu L.T. and Hung W.C. (2004). Involvement of histone deacetylation in ras-induced down-regulation of the metastasis supressor RECK. Cell Signal. 16, 675-679.
4. Cho Y.B., Lee W.Y., Song S.Y., Shin H.J., Yun S.H. and Chun H.K. (2007). Matrix metalloproteinase-9 activity is associated with poor prognosis in T3-T4 node-negative colorectal cancer. Hum. Pathol. 38, 1603-1610.
5. Coussens L.M., Fingleton B. and Matrisian L.M. (2002). Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295, 2387-2392.
6. Cox G. and O'Byrne K.J. (2001). Matrix metalloproteinases and cancer. Anticancer Res. 21, 4207-4219.
7. Egeblad M. and Werb Z. (2002). New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer. 2, 161-174.
8. Eisenberg I., Hochner H., Sadeh M., Argov Z. and Mitrani-Rosenbaum S. (2002). Establishment of the genomic structure and identification of thirteen single-nucleotide polymorphisms in the human RECK gene. Cytogenet. Genome Res. 97, 58-61.
9. Fata J.E., Leco K.J., Voura E.B., Yu H.Y., Waterhouse P., Murphy G., Moorehead R.A. and Khokha R. (2001). Accelerated apoptosis in the Timp-3-deficient mammary gland. J. Clin. Invest. 108, 831-841.
10. Folkman J. (2006). Angiogenesis. Annu. Rev. Med. 57, 1-18.
11. Folkman J., Watson K., Ingber D. and Hanahan D. (1989). Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339, 58-61.
12. Furumoto K., Arii S., Mori A., Furuyama H., Gorrin Rivas M.J., Nakao T., Isobe N., Murata T., Takahashi C., Noda M. and Imamura M. (2001). RECK gene expression in hepatocellular carcinoma: correlation with invasion-related clinicopathological factors and its clinical significance. Reverse-inducing--cysteine-rich protein with Kazal motifs. Hepatology 33, 189-195.
13. Heissig B., Hattori K., Friedrich M., Rafii S. and Werb Z. (2003). Angiogenesis: vascular remodeling of the extracellular matrix involves metalloproteinases. Curr. Opin. Hematol. 10, 136-141.
14. Hidalgo M. and Eckhardt S.G. (2001). Development of matrix metalloproteinase inhibitors in cancer therapy. J. Natl. Cancer. Inst. 93, 178-193.
15. Hlatky L., Hahnfeldt P. and Folkman J. (2002). Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J. Natl. Cancer Inst. 94, 883-893.
16. Hsu M.C., Chang H.C. and Hung W.C. (2006). HER-2/neu represses the metastasis suppressor RECK via ERK and Sp transcription factors to promote cell invasion. J. Biol. Chem. 281, 4718-4725.
17. Iizasa T., Fujisawa T., Suzuki M., Motohashi S., Yasufuku K., Yasukawa T., Baba M. and Shiba M. (1999). Elevated levels of circulating plasma matrix metalloproteinase 9 in non-small cell lung cancer patients. Clin. Cancer Res. 5, 149-153.
18. Jadhav U., Chigurupati S., Lakka S.S. and Mohanam S. (2004). Inhibition of matrix metalloproteinase-9 reduces in vitro invasion and angiogenesis in human microvascular endothelial cells. Int. J. Oncol. 25, 1407-1414.
19. Kern A., Taubert H., Scheele J., Rudroff C., Mothes H., Kappler M., Bartel F. and Richter K.K. (2002). Association of p53 mutations, microvessel density and neoangiogenesis in pairs of colorectal cancers and corresponding liver metastases. Int. J. Oncol. 21, 243-249.
20. Kitayama H., Sugimoto Y., Matsuzaki T., Ikawa Y. and Noda M. (1989). A ras-related gene with transformation suppressor activity. Cell. 56, 77-84.
21. Lakka S.S., Gondi C.S., Dinh D.H., Olivero W.C., Gujrati M., Rao V.H., Sioka C. and Rao J.S. (2005). Specific interference of urokinasetype plasminogen activator receptor and matrix metalloproteinase-9 gene expression induced by double-stranded RNA results in decreased invasion, tumor growth, and angiogenesis in gliomas. J. Biol. Chem. 280, 21882-21892.
22. Leco K.J., Waterhouse P., Sanchez O.H., Gowing K.L., Poole A.R., Wakeham A., Mak T.W. and Khokha R. (2001). Spontaneous air space enlargement in the lungs of mice lacking tissue inhibitor of metalloproteinases-3 (TIMP-3). J. Clin. Invest. 108, 817-829.
23. Li Y., Zhang Y. and Zheng Q. (2005). Expression of RECK gene and MMP-9 in hilar cholangiocarcinoma and its clinical significance. J. Huazhong. Univ. Sci. Technolog. Med. Sci. 25, 552-554.
24. Liu L.T., Chang H.C., Chiang L.C. and Hung W.C. (2002). Induction of RECK by nonsteroidal anti-inflammatory drugs in lung cancer cells. Oncogene 21, 8347-8350.
25. Liu L.T., Chang H.C., Chiang L.C. and Hung W.C. (2003a). Histone deacetylase inhibitor up-regulates RECK to inhibit MMP-2 activation and cancer cell invasion. Cancer Res. 63, 3069-3072.
26. Liu L.T., Peng J.P., Chang H.C. and Hung W.C. (2003b). RECK is a target of Epstein-Barr virus latent membrane protein 1. Oncogene 22, 8263-8270.
27. Lukashev M.E. and Werb Z. (1998). ECM signalling: orchestrating cell behaviour and misbehaviour. Trends Cell. Biol. 8, 437-441.
28. Majello B., De Luca P. and Lania L. (1997). Sp3 is a bifunctional transcription regulator with modular independent activation and repression domains. J. Biol. Chem. 272, 4021-4026.
29. Masui T., Doi R., Koshiba T., Fujimoto K., Tsuji S., Nakajima S., Koizumi M., Toyoda E., Tulachan S., Ito D., Kami K., Mori T., Wada M., Noda M. and Imamura M. (2003). RECK expression in pancreatic cancer: its correlation with lower invasiveness and better prognosis. Clin. Cancer Res. 9, 1779-1784.
30. McCawley L.J. and Matrisian L.M. (2001). Matrix metalloproteinases: they're not just for matrix anymore! Curr. Opin. Cell Biol. 13, 534-540.
31. Molina J.R., Reid J.M., Erlichman C., Sloan J.A., Furth A., Safgren S.L., Lathia C.D. and Alberts S.R. (2005). A phase I and pharmacokinetic study of the selective, non-peptidic inhibitor of matrix metalloproteinase BAY 12-9566 in combination with etoposide and carboplatin. Anticancer Drugs. 16, 997-1002.
32. Mook O.R., Frederiks W.M. and Van Noorden C.J. (2004). The role of gelatinases in colorectal cancer progression and metastasis. Biochim. Biophys. Acta. 1705, 69-89.
33. Mori T., Moriuchi R., Okazaki E., Yamada K. and Katamine S. (2007). Tgat oncoprotein functions as a inhibitor of RECK by association of the unique C-terminal region. Biochem. Biophys. Res. Commun. 355, 937-943.
34. Moses M.A., Sudhalter J. and Langer R. (1990). Identification of an inhibitor of neovascularization from cartilage. Science 248, 1408-1410.
35. Murphy G., Knauper V., Cowell S., Hembry R., Stanton H., Butler G., Freije J., Pendas A.M. and Lopez-Otin C. (1999). Evaluation of some newer matrix metalloproteinases. Ann. NY Acad. Sci. 878, 25-39.
36. Nagase H., Visse R. and Murphy G. (2006). Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc. Res. 69, 562-573.
37. Niedergethmann M., Hildenbrand R., Wostbrock B., Hartel M., Sturm J.W., Richter A. and Post S. (2002). High expression of vascular endothelial growth factor predicts early recurrence and poor prognosis after curative resection for ductal adenocarcinoma of the pancreas. Pancreas 25, 122-129.
38. Noda M., Kitayama H., Matsuzaki T., Sugimoto Y., Okayama H., Bassin R.H. and Ikawa Y. (1989). Detection of genes with a potential for suppressing the transformed phenotype associated with activated ras genes. Proc. Natl. Acad. Sci. USA 86, 162-166.
39. Noda M., Oh J., Takahashi R., Kondo S., Kitayama H. and Takahashi C. (2003). RECK: a novel suppressor of malignancy linking oncogenic signaling to extracellular matrix remodeling. Cancer Metastasis Rev. 22, 167-175.
40. Oh J., Seo D.W., Diaz T., Wei B., Ward Y., Ray J.M., Morioka Y., Shi S., Kitayama H., Takahashi C., Noda M. and Stetler-Stevenson W.G. (2004). Tissue inhibitors of metalloproteinase 2 inhibits endothelial cell migration through increased expression of RECK. Cancer Res. 64, 9062-9069.
41. Oh J., Takahashi R., Kondo S., Mizoguchi A., Adachi E., Sasahara R.M., Nishimura S., Imamura Y., Kitayama H., Alexander D.B., Ide C., Horan T.P., Arakawa T., Yoshida H., Nishikawa S., Itoh Y., Seiki M., Itohara S., Takahashi C. and Noda M. (2001). The membraneanchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell 107, 789-800.
42. Pang R.T., Lee L.T., Ng S.S., Yung W.H. and Chow B.K. (2004). CpG methylation and transcription factors Sp1 and Sp3 regulate the expression of the human secretin receptor gene. Mol. Endocrinol. 18, 471-483.
43. Raffetto J.D. and Khalil R.A. (2008). Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem. Pharmacol. 75, 346-359.
44. Rhee J.S. and Coussens L.M. (2002). RECKing MMP function: implications for cancer development. Trends Cell Biol. 12, 209-211.
45. Rizvi N.A., Humphrey J.S., Ness E.A., Johnson M.D., Gupta E., Williams K., Daly D.J., Sonnichsen D., Conway D., Marshall J. and Hurwitz H. (2004). A phase I study of oral BMS-275291, a novel nonhydroxamate sheddase-sparing matrix metalloproteinase inhibitor, in patients with advanced or metastatic cancer. Clin. Cancer Res. 10, 1963-1970.
46. Sasahara R.M., Brochado S.M., Takahashi C., Oh J., Maria-Engler S.S., Granjeiro J.M., Noda M. and Sogayar M.C. (2002). Transcriptional control of the RECK metastasis/angiogenesis suppressor gene. Cancer Detect Prev. 26, 435-443.
47. Sasahara R.M., Takahashi C. and Noda M. (1999). Involvement of the Sp1 site in ras-mediated downregulation of the RECK metastasis suppressor gene. Biochem. Biophys. Res. Commun. 264, 668-675.
48. Sato H., Takino T., Okada Y., Cao J., Shinagawa A., Yamamoto E. and Seiki M. (1994). A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 370, 61-65.
49. Song S.Y., Son H.J., Nam E., Rhee J.C. and Park C. (2006). Expression of reversion-inducing-cysteine-rich protein with Kazal motifs (RECK) as a prognostic indicator in gastric cancer. Eur. J. Cancer 42, 101-108.
50. Sounni N.E., Devy L., Hajitou A., Frankenne F., Munaut C., Gilles C., Deroanne C., Thompson E.W., Foidart J.M. and Noel A. (2002). MT1-MMP expression promotes tumor growth and angiogenesis through an up-regulation of vascular endothelial growth factor expression. FASEB J. 16, 555-564.
51. Span P.N., Sweep C.G., Manders P., Beex L.V., Leppert D. and Lindberg R.L. (2003). Matrix metalloproteinase inhibitor reversioninducing cysteine-rich protein with Kazal motifs: a prognostic marker for good clinical outcome in human breast carcinoma. Cancer 97, 2710-2715.
52. Sternlicht M.D. and Werb Z. (2001). How matrix metalloproteinases regulate cell behavior. Annu. Rev. Cell Dev. Biol. 17, 463-516.
53. Sun X.F. and Zhang H. (2006). Clinicopathological significance of stromal variables: angiogenesis, lymphangiogenesis, inflammatory infiltration, MMP and PINCH in colorectal carcinomas. Mol. Cancer. 5, 43.
54. Takahashi C., Akiyama N., Matsuzaki T., Takai S., Kitayama H. and Noda M. (1996). Characterization of a human MSX-2 cDNA and its fragment isolated as a transformation suppressor gene against v-Kiras oncogene. Oncogene 12, 2137-2146.
55. Takahashi C., Sheng Z., Horan T.P., Kitayama H., Maki M., Hitomi K., Kitaura Y., Takai S., Sasahara R.M., Horimoto A., Ikawa Y., Ratzkin B.J., Arakawa T. and Noda M. (1998). Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK. Proc. Natl. Acad. Sci USA 95, 13221-13226.
56. Takenaka K., Ishikawa S., Kawano Y., Yanagihara K., Miyahara R., Otake Y., Morioka Y., Takahashi C., Noda M., Wada H. and Tanaka F. (2004). Expression of a novel matrix metalloproteinase regulator, RECK, and its clinical significance in resected non-small cell lung cancer. Eur. J. Cancer. 40, 1617-1623.
57. Takeuchi T., Hisanaga M., Nagao M., Ikeda N., Fujii H., Koyama F., Mukogawa T., Matsumoto H., Kondo S., Takahashi C., Noda M. and Nakajima Y. (2004). The membrane-anchored matrix metalloproteinase (MMP) regulator RECK in combination with MMP- 9 serves as an informative prognostic indicator for colorectal cancer. Clin. Cancer Res. 10, 5572-5579.
58. Toth M., Chvyrkova I., Bernardo M.M., Hernandez-Barrantes S. and Fridman R. (2003). Pro-MMP-9 activation by the MT1-MMP/MMP-2 axis and MMP-3: role of TIMP-2 and plasma membranes. Biochem. Biophys. Res. Commun. 308, 386-395.
59. van der Jagt, M.F., Sweep F.C., Waas E.T., Hendriks T., Ruers T.J., Merry A.H., Wobbes T. and Span P.N. (2006). Correlation of reversion-inducing cysteine-rich protein with kazal motifs (RECK) and extracellular matrix metalloproteinase inducer (EMMPRIN), with MMP-2, MMP-9, and survival in colorectal cancer. Cancer Lett. 237, 289-297.
60. van Lent P.L., Span P.N., Sloetjes A.W., Radstake T.R., van Lieshout A.W., Heuvel J.J., Sweep C.G. and van den Berg W.B. (2005). Expression and localisation of the new metalloproteinase inhibitor RECK (reversion inducing cysteine-rich protein with Kazal motifs) in inflamed synovial membranes of patients with rheumatoid arthritis. Ann. Rheum. Dis. 64, 368-374.
61. Visse R. and Nagase H. (2003). Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res. 92, 827-839.
62. Vu T.H. and Werb Z. (2000). Matrix metalloproteinases: effectors of development and normal physiology. Genes Dev. 14, 2123-2133.
63. Weaver V.M. (2002). Membrane-associated MMP regulators: novel cell adhesion tumor suppressor proteins? Dev. Cell. 2, 6-7.
64. Welm B., Mott J. and Werb Z. (2002). Developmental biology: vasculogenesis is a wreck without RECK. Curr. Biol. 12, R209-211.
65. Wendum D., Boelle P.Y., Rigau V., Sebbagh N., Olschwang S., Mourra N., Parc R., Trugnan G., Masliah J. and Flejou J.F. (2003). Mucinous colon carcinomas with microsatellite instability have a lower microvessel density and lower vascular endothelial growth factor expression. Virchows Arch. 442, 111-117.
66. Will H., Atkinson S.J., Butler G.S., Smith B. and Murphy G. (1996). The soluble catalytic domain of membrane type 1 matrix metalloproteinase cleaves the propeptide of progelatinase A and initiates autoproteolytic activation. Regulation by TIMP-2 and TIMP-3. J. Biol. Chem. 271, 17119-17123.
67. Wong W.K., Chen K. and Shih J.C. (2003). Decreased methylation and transcription repressor Sp3 up-regulated human monoamine oxidase (MAO) B expression during Caco-2 differentiation. J. Biol. Chem. 278, 36227-36235.
68. Yoshizuka N., Moriuchi R., Mori T., Yamada K., Hasegawa S., Maeda T., Shimada T., Yamada Y., Kamihira S., Tomonaga M. and Katamine S. (2004). An alternative transcript derived from the trio locus encodes a guanosine nucleotide exchange factor with mouse cell-transforming potential. J. Biol. Chem. 279, 43998-44004.
69. Zhou X., Richon V.M., Rifkind R.A. and Marks P.A. (2000). Identification of a transcriptional repressor related to the noncatalytic domain of histone deacetylases 4 and 5. Proc. Natl. Acad. Sci. USA 97, 1056-1061.
70. Zucker S., Cao J. and Chen W.T. (2000). Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene 19, 6642-6650.